Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Organisation › Details

Follicum AB

Follicum is a biotech company focusing on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, Follicums research has resulted in a new peptide class which significantly increases the release of insulin in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Spotlight since 2014. *

 

Period Start 2011-01-01 established
Product Industry peptide-based drug
Persons Person Alenfall, Jan (Follicum 201902 CEO)
  Person 2 Gårdemyr, Gunnar (Follicum 201902 before Targovax/Polaris + Nycomed/Takeda)
     
Region Region Lund
  Country Sweden
  Street 22 Scheelevägen
  City 22363 Lund
  Tel +46-46-192197
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for »About Section«: Follicum AB. (2/11/19). "Press Release: Follicum Selects Novel Peptide Drug Candidate for the Treatment of Diabetes and Protection of Beta Cells".
     
   
Record changed: 2024-02-12

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Follicum AB


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Top News How Covid Effects the Brain 650x300px




» top